Although the incidence of PCa has more than tripled between 1990 and 2015 (4), also due to an increase in the diffusion of prostate-specific antigen (PSA) screening that aided in early cancer detection and diagnosis (5), mortality rates have been decreasing in most Western countries thanks to improved diagnosis and treatment (6). This evidence concerns the gene KLK3 and posterior cortical atrophy.